CN115667314A - T细胞双特异性结合蛋白 - Google Patents

T细胞双特异性结合蛋白 Download PDF

Info

Publication number
CN115667314A
CN115667314A CN202180035812.8A CN202180035812A CN115667314A CN 115667314 A CN115667314 A CN 115667314A CN 202180035812 A CN202180035812 A CN 202180035812A CN 115667314 A CN115667314 A CN 115667314A
Authority
CN
China
Prior art keywords
bispecific
amino acid
seq
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035812.8A
Other languages
English (en)
Chinese (zh)
Inventor
拉胡尔·帕尔乔杜里
布拉德利·R·皮尔斯
李青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRISPR Therapeutics AG
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of CN115667314A publication Critical patent/CN115667314A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180035812.8A 2020-03-16 2021-03-16 T细胞双特异性结合蛋白 Pending CN115667314A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990281P 2020-03-16 2020-03-16
US62/990,281 2020-03-16
PCT/US2021/022626 WO2021188590A2 (en) 2020-03-16 2021-03-16 T-cell bispecific binding proteins

Publications (1)

Publication Number Publication Date
CN115667314A true CN115667314A (zh) 2023-01-31

Family

ID=77768281

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035812.8A Pending CN115667314A (zh) 2020-03-16 2021-03-16 T细胞双特异性结合蛋白

Country Status (7)

Country Link
US (1) US20230183344A1 (https=)
EP (1) EP4121462A4 (https=)
JP (1) JP2023520636A (https=)
CN (1) CN115667314A (https=)
AU (1) AU2021239929A1 (https=)
CA (1) CA3171709A1 (https=)
WO (1) WO2021188590A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874942A (zh) * 2025-03-28 2025-04-25 核欣(苏州)医药科技有限公司 一种放射性蛋白偶联药物及其应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4638505A1 (en) * 2022-12-21 2025-10-29 Erasmus University Rotterdam Medical Center Bispecific antibodies targeting cd117 and cd3
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170298148A1 (en) * 2014-02-12 2017-10-19 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
CN107646038A (zh) * 2015-05-28 2018-01-30 基因泰克公司 用于检测抗cd3同二聚体的基于细胞的测定
CN108290939A (zh) * 2015-10-16 2018-07-17 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
JP2018529317A (ja) * 2015-07-31 2018-10-11 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ メソテリン及びｃｄ３に結合する二重特異性抗体構築物
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US20190153114A1 (en) * 2017-10-24 2019-05-23 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
CN109073635A (zh) * 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
US10538579B2 (en) * 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
GB201912681D0 (en) * 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170298148A1 (en) * 2014-02-12 2017-10-19 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
CN107646038A (zh) * 2015-05-28 2018-01-30 基因泰克公司 用于检测抗cd3同二聚体的基于细胞的测定
JP2018529317A (ja) * 2015-07-31 2018-10-11 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ メソテリン及びｃｄ３に結合する二重特異性抗体構築物
CN108290939A (zh) * 2015-10-16 2018-07-17 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US20190153114A1 (en) * 2017-10-24 2019-05-23 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874942A (zh) * 2025-03-28 2025-04-25 核欣(苏州)医药科技有限公司 一种放射性蛋白偶联药物及其应用

Also Published As

Publication number Publication date
CA3171709A1 (en) 2021-09-23
WO2021188590A2 (en) 2021-09-23
AU2021239929A1 (en) 2022-10-13
EP4121462A4 (en) 2024-04-24
JP2023520636A (ja) 2023-05-18
WO2021188590A3 (en) 2022-07-21
EP4121462A2 (en) 2023-01-25
US20230183344A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
CN115667314A (zh) T细胞双特异性结合蛋白
CN111601825B (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
CN109715667B (zh) 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN107660214B (zh) 针对cd3和cd20的双特异性抗体
JP7058219B2 (ja) Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
RU2684595C2 (ru) Ковалентно связанные конъюгаты антиген-антитело
US11098099B2 (en) Interleukin-2 fusion proteins and uses thereof
JP2021524249A (ja) 抗ｃｄ３抗体及びその使用
KR20170084327A (ko) Cd3 및 cd38에 결합하는 이형이량체 항체
TWI814749B (zh) 三Fab‐康特斯體(Contorsbody)
CN107074956A (zh) Cd123结合剂及其用途
CN102958942A (zh) 异二聚体结合蛋白及其应用
CN114828965A (zh) 与hla-a2/mage-a4结合的抗体
JP2018515086A (ja) 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
BR112020007736A2 (pt) composição e método de tratamento
CN113056486B (zh) 改善的抗flt3抗原结合蛋白
JP2019524681A (ja) 新規抗体フォーマット
KR20180030917A (ko) 항-cd154 항체 및 그의 사용 방법
CA3214283A1 (en) Anti-cd19 antibodies and car-t structures
WO2019084053A1 (en) COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN114340668A (zh) 结合于cd38和cd3的异源二聚抗体
CN114867751B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
EP4592319A1 (en) Antibodies capable of specifically binding tnf-like ligand 1a and use thereof
KR20260051042A (ko) 단일 및 다중특이성 항-trem2 항체, 그 방법 및 용도
TW202542186A (zh) 抗體

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230721

Address after: Swiss Express

Applicant after: CRISPR THERAPEUTICS AG

Address before: Massachusetts

Applicant before: MAGENTA THERAPEUTICS, Inc.